APRIL promotes B-1 cell-associated neoplasm

被引:129
作者
Planelles, L
Carvalho-Pinto, CE
Hardenberg, G
Smaniotto, S
Savino, W
Gómez-Caro, R
Alvarez-Mon, M
de Jong, J
Eldering, E
Martínez-A, C
Medema, JP
Hahne, M
机构
[1] CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain
[2] Inst Genet Mol Montpellier, CNRS UMR5535, F-34293 Montpellier 5, France
[3] Leiden Univ, Med Ctr, Dept Clin Oncol, NL-2333 ZA Leiden, Netherlands
[4] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Dept Immunol, Rio De Janeiro E 28801, Brazil
[5] Univ Alcala de Henares, CSIC, Unidad Mixta UA, Madrid 21045, Spain
[6] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands
关键词
D O I
10.1016/j.ccr.2004.08.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A tumor-supporting role for the TNF-like ligand APRIL has been suggested. Here we describe that 9- to 12-month-old APRIL transgenic mice develop lymphoid tumors that originate from expansion of the peritoneal B-1 B cell population. Aging APRIL transgenic mice develop progressive hyperplasia in mesenteric lymph nodes and Peyer's patches, disorganization of affected lymphoid tissues, mucosal and capsular infiltration, and eventual tumor cell infiltration into nonlymphoid tissues such as kidney and liver. We detected significantly increased APRIL levels in sera of B cell chronic lymphoid leukemia (B-CLL) patients, indicating that APRIL promotes onset of B-1-associated neoplasms and that APRIL antagonism may provide a therapeutic strategy to treat B-CLL patients.
引用
收藏
页码:399 / 408
页数:10
相关论文
共 29 条
  • [1] ANDREEFF M, 1980, BLOOD, V55, P282
  • [2] Flow cytometric quantification of tumour endothelial cells; an objective alternative for microvessel density assessment
    Baeten, CIM
    Wagstaff, J
    Verhoeven, ICL
    Hillen, HFP
    Griffioen, AW
    [J]. BRITISH JOURNAL OF CANCER, 2002, 87 (03) : 344 - 347
  • [3] Update on the biology of chronic lymphocytic leukemia
    Bannerji, R
    Byrd, JC
    [J]. CURRENT OPINION IN ONCOLOGY, 2000, 12 (01) : 22 - 29
  • [4] Origins and functions of B-1 cells with notes on the role of CD5
    Berland, R
    Wortis, HH
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2002, 20 : 253 - 300
  • [5] Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression
    Bichi, R
    Shinton, SA
    Martin, ES
    Koval, A
    Calin, GA
    Cesari, R
    Russo, G
    Hardy, RR
    Croce, CM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (10) : 6955 - 6960
  • [6] Impaired IgA class switching in APRIL-deficient mice
    Castigli, E
    Scott, S
    Dedeoglu, F
    Bryce, P
    Jabara, H
    Bhan, AK
    Mizoguchi, E
    Geha, RS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (11) : 3903 - 3908
  • [7] Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma
    Czarneski, J
    Lin, YC
    Chong, S
    McCarthy, B
    Fernandes, H
    Parker, G
    Mansour, A
    Huppi, K
    Marti, GE
    Raveche, E
    [J]. LEUKEMIA, 2004, 18 (03) : 597 - 606
  • [8] Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor
    Deshayes, F
    Laprée, G
    Portier, A
    Richard, Y
    Pencalet, P
    Mahieu-Caputo, D
    Horellou, P
    Tsapis, A
    [J]. ONCOGENE, 2004, 23 (17) : 3005 - 3012
  • [9] Fagarasan S, 2000, IMMUNOL REV, V176, P205
  • [10] APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth
    Hahne, M
    Kataoka, T
    Schröter, M
    Hofmann, K
    Irmler, M
    Bodmer, JL
    Schneider, P
    Bornard, T
    Holler, N
    French, LE
    Sordat, B
    Rimoldi, D
    Tschopp, J
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (06) : 1185 - 1190